What was the primary driver of the significant decrease in earnings for the quarter?

The primary driver for the significant decrease in earnings was a substantial increase in reserves for liabilities related to litigation and other legal matters, totaling $455 million. This included provisions for private litigation, governmental investigations concerning wholesaler inventory and accounting, and product liability.

How did sales perform across the company's segments?

Overall sales increased by 6% to $5.4 billion. The Pharmaceuticals segment saw a 6% increase driven by key products like PLAVIX* and ABILIFY*, despite some exclusivity losses. The Oncology Therapeutics Network segment grew 9%, while Other Healthcare increased 14%. The Nutritionals segment experienced a 2% decrease, partly due to the divestiture of its Adult Nutritional business.

What is the outlook regarding the company's numerous legal proceedings?

Management continues to believe that the aggregate impact of ongoing legal matters, beyond current reserves, is reasonably likely to be material to the company's results of operations and cash flows in the next few years, and could also be material to its financial condition and liquidity. The company has increased reserves to address these matters.

How is the company managing R&D investments and pipeline development?

Bristol-Myers Squibb continues to invest heavily in R&D, with expenditures increasing by 19% to $625 million in the second quarter. The company is focusing on ten disease areas and advancing compounds in Phase III development, including collaborations like the one with Merck for muraglitazar for Type 2 diabetes.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2004

Summary

Bristol-Myers Squibb Company (BMY) reported financial results for the second quarter and first half of 2004, reflecting a mixed performance characterized by sales growth offset by significant legal expenses. Total sales for the second quarter of 2004 increased by 6% year-over-year to $5.4 billion, driven by volume, favorable foreign exchange, and pricing. However, earnings before minority interest and income taxes saw a substantial decrease of 38% to $775 million, primarily due to an increase in reserves for litigation and legal matters totaling $455 million. Net earnings declined by 42% to $527 million, impacting earnings per share. The company continues to invest in research and development, with expenditures increasing by 19% in the second quarter to $625 million. Key product areas like Pharmaceuticals, Oncology Therapeutics Network, Nutritionals, and Other Healthcare showed varied performance. Pharmaceutical sales saw growth driven by key brands like PLAVIX* and ABILIFY*, but were impacted by ongoing exclusivity losses for some products. The significant legal reserves and a write-off of in-process research and development related to an acquisition were major factors affecting profitability.

Key Highlights

1Total sales for Q2 2004 increased 6% to $5.4 billion, driven by volume, foreign exchange, and pricing.
2Earnings before minority interest and income taxes decreased 38% to $775 million due to a significant increase in litigation reserves ($455 million).
3Net earnings decreased 42% to $527 million, with EPS falling to $0.27 (diluted) from $0.46 in the prior year.
4Research and Development expenses increased 19% to $625 million, reflecting continued investment in new products and late-stage pipeline.
5Pharmaceutical segment sales grew 6% to $3.8 billion, supported by strong performance of PLAVIX*, ABILIFY*, and ERBITUX*, but impacted by exclusivity losses for other products.
6The company divested its Adult Nutritional business to Novartis for $385 million, recording a pre-tax gain of $313 million.
7Significant legal proceedings and investigations related to wholesaler inventory, accounting matters, and product liability continue to be a major focus, with increased reserves impacting current period results.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2004

Summary

Key Highlights

Frequently Asked Questions